OncoPharm
@bossaer.bsky.social
馃摛 82
馃摜 48
馃摑 8
John Bossaer, PharmD, BCOP. Professors @ ETSU and host/producer of the OncoPharm podcast
ascopubs.org/doi/abs/10.1...
7 months ago
0
0
0
reposted by
OncoPharm
Eric Topol
10 months ago
New evidence
@nejm.org
today that age-related clonal hematopoiesis (CHIP) has a driver role in evolution of solid cancers
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
loading . . .
Clonal Hematopoiesis as a Driver of Solid Tumors | NEJM
Clonal hematopoiesis is the expansion of a genetically related population of hematopoietic stem and progenitor cells that disproportionately contribute to blood-cell production.1 Clonal hematopoies...
https://www.nejm.org/doi/full/10.1056/NEJMe2504775
3
140
35
reposted by
OncoPharm
10 months ago
Another great OncoPharm podcast episode out today. If you鈥檙e heading to
#HOPA2025
, do yourself a favor and download to listen on your travels.
@bossaer.bsky.social
has excellent recs for fun outside the conference!
podcasts.apple.com/us/podcast/o...
loading . . .
Expanded Approvals for Durvalumab, Lu 177 vt; Portland Preview
Podcast Episode 路 OncoPharm 路 04/08/2025 路 12m
https://podcasts.apple.com/us/podcast/oncopharm/id1305345744?i=1000702626933
0
1
1
This week鈥檚 Pod
open.spotify.com/episode/6UGu...
loading . . .
AMPLIFY
OncoPharm 路 Episode
https://open.spotify.com/episode/6UGudDWT4AeyWVxYLhWw1z?si=lq41vt8_TUGjoFm7QcLXiw
12 months ago
0
3
0
reposted by
OncoPharm
12 months ago
Cool paper out of @UFPharmacy on integrating the Epic PGx module. It's going on the required reading list next time I take pharmacy students.
pubmed.ncbi.nlm.nih.gov/39960348/
loading . . .
Implementing Pharmacogenomics Clinical Decision Support: A Comprehensive Tutorial on how to Integrate the Epic Genomics Module - PubMed
In the past decade, pharmacogenomic (PGx) testing to predict drug response have emerged into clinical care. Clinical decision support (CDS) has and continues to play a key role in educating prescriber...
https://pubmed.ncbi.nlm.nih.gov/39960348/
0
2
1
Acute leukemia diagnosis by day of the week
pmc.ncbi.nlm.nih.gov/articles/PMC...
about 1 year ago
1
3
1
Tal-Tec or Tec-Tal?
www.nejm.org/doi/full/10....
loading . . .
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma | NEJM
Talquetamab (anti鈥揋 protein鈥揷oupled receptor family C group 5 member D) and teclistamab (anti鈥揃-cell maturation antigen) are bispecific antibodies that activate T cells by targeting CD3 and that ha...
https://www.nejm.org/doi/full/10.1056/NEJMoa2406536
about 1 year ago
0
1
0
ascopubs.org/doi/10.1200/...
loading . . .
Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration | JCO Oncology Practice
PURPOSETeclistamab is initiated with a step-up dosing (SUD) schedule to mitigate the risk of cytokine release syndrome (CRS) and immune effector cell鈥揳ssociated neurotoxicity syndrome (ICANS). Early t...
https://ascopubs.org/doi/10.1200/OP-24-00489
about 1 year ago
0
2
1
reposted by
OncoPharm
Jarushka Naidoo
about 1 year ago
Can gender & genetics impact alectinib tox?
@jtoonline.bsky.social
- 215pts with ALK+ NSCLC - women had 猬嗭笍g3+ tox (f v m: 56% v 34% p=0.001), 35% had 猬嗭笍trough levels p<0.001 - Pts with SNP affecting alectinib metabolism (PPAR-伪 209G>A) had 猬嗭笍g3+ tox
#Medsky
#Oncsky
#LCSM
www.jto.org/article/S155...
loading . . .
Sex and common germline variants impact the toxicity profile and pharmacokinetics of alectinib: a nation-wide cohort study in patients with ALK-positive non-small cell lung cancer
Alectinib, a small-molecule kinase inhibitor, is used as first-line treatment for anaplastic lymphoma kinase鈥損ositive (ALK+) non-small cell lung cancer (NSCLC). Albeit generally well-tolerated, a considerable subset of patients requires dose adjustments due to drug-related toxicity. Single-nucleotide polymorphisms (SNPs) in genes related to the metabolism of alectinib may upfront identify patients at risk for toxicity.
https://www.jto.org/article/S1556-0864%2824%2902488-2/fulltext
0
30
14
open.spotify.com/episode/6Y0k...
about 1 year ago
0
0
0
reposted by
OncoPharm
Peter Hall
about 1 year ago
This is how we should be doing Oncology trials - the Dutch SONIA trial looking at treatment sequencing of CDK 4/6 inhibitors in advanced breast cancer. A self funding efficiency trial!
#oncsky
www.nature.com/articles/s41...
loading . . .
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer - Nature
The phase 3 SONIA trial challenges the benefits of using cyclin-dependent kinase 4 and 6 inhibitors as a first-line compared with second-line treatment.
https://www.nature.com/articles/s41586-024-08035-2#citeas
1
21
8
Gee! The traffic is terrific!!
about 1 year ago
0
0
0
This week鈥檚 pod is on the 1st menin inhibitor FDA approved
open.spotify.com/episode/28yS...
loading . . .
Revumenib
OncoPharm 路 Episode
https://open.spotify.com/episode/28ySEyFGXdjK4xlG7O4vrv?si=9-fBSVylQAiEmxhsiZwsqg
about 1 year ago
0
1
0
you reached the end!!
feeds!
log in